Last update 01 Nov 2024

30S subunit x cPLA2α x GR

Basic Info

Related Targets
30S subunitcPLA2αGR

Related

1
Drugs associated with 30S subunit x cPLA2α x GR
Loteprednol Etabonate/Tobramycin
Target
30S subunit x GR x cPLA2α
Mechanism
30S subunit inhibitors [+2]
Active Org.
Bausch & Lomb, Inc.Bausch & Lomb, Inc.
Originator Org.
Bausch & Lomb, Inc.Bausch & Lomb, Inc.
Active Indication
Ocular inflammation
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date14 Dec 2004
2
Clinical Trials associated with 30S subunit x cPLA2α x GR
NCT01456780 / CompletedPhase 4IIT
Relative Efficacy of Loteprednol (Lotemax®) vs. Loteprednol/Tobramycin (Zylet®) in Treatment of Chronic Ocular Surface Inflammation Associated With Meibomian Gland Dysfunction (MGD)/Posterior Blepharitis
NCT00420628 / CompletedPhase 4
A Safety and Efficacy Study of Zylet® (Loteprednol Etabonate 0.5% and Tobramycin 0.3% Ophthalmic Suspension) Compared to Vehicle in the Management of Lid Inflammation (Chalazion/Hordeolum) in Pediatric Subjects
100 Clinical Results associated with 30S subunit x cPLA2α x GR
Login to view more data
100 Translational Medicine associated with 30S subunit x cPLA2α x GR
Login to view more data
0 Patents (Medical) associated with 30S subunit x cPLA2α x GR
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free